

News and Deals

1. Georgiamune: \$92.7M Series B for immune reprogramming in cancer and autoimmune disease | Aug. 17, 2026

CB Insights tracked a \$92.7M Series B for clinical-stage Georgiamune, with General Catalyst and eLab Ventures among the investor set. The company is advancing immunomodulators designed to restore immune balance across oncology and autoimmune indications.

HDIG take: Life-science relevance: large Series B supports a platform aimed at high-value immune signaling pathways. [LINK](#)

2. Leal Therapeutics: \$30M Series A extension for neuro-metabolic CNS therapeutics | Aug. 17, 2026

VC News Daily reported Leal Therapeutics completed a \$30M second close of its Series A. CB Insights also tracked the round, including Eli Lilly as a new investor alongside OrbiMed, DDF, Newpath, Chugai Venture Fund and others.

HDIG take: Biotech signal: capital extends clinical-stage work in ALS, schizophrenia and other high-need CNS disorders. [LINK](#); [LINK](#)

3. Bridge to Life: \$110M Series C and debt financing for organ preservation and perfusion tech | Aug. 13, 2026

VC News Daily reported Bridge to Life completed a \$110M Series C and debt financing. The company sells organ preservation solutions and perfusion technologies used in transplant workflows.

HDIG take: Medtech relevance: transplant preservation remains a specialized, high-acuity market with room for platform expansion. [LINK](#)

4. InduPro: \$77M Series B to advance cell-surface protein interaction therapeutics | Aug. 12, 2026

InduPro raised a \$77M Series B, according to CB Insights, with The Column Group leading and investors including Eli Lilly, Sanofi, MRL Ventures, Vida Ventures and others participating.

HDIG take: Platform biotech: maps and manipulates cell-surface interactions to build new therapeutic signaling logic. [LINK](#)

5. Infinimmune: \$75M Series A for human-derived antibody medicines | Aug. 11, 2026

CB Insights tracked a \$75M Series A for Infinimmune, co-led by Playground Global and Regeneron Ventures, with RA Capital, Merck GHI Fund, Forge Life Science Partners and others participating.

HDIG take: Drug discovery: antibody engineering from rare human immune responses remains a fertile area for differentiated biologics. [LINK](#)

6. Boulevard Bio: \$65M stealth launch for a Deerfield-backed biotech platform | Aug. 12, 2026

VC News Daily reported Boulevard Bio emerged from stealth with \$65M from founding investor Deerfield Management. The company is positioned as an early-stage life-science platform company.

HDIG take: Formation signal: sizable stealth launch indicates an investor-built biotech with room for pipeline definition. [LINK](#)

7. Vedanta Biosciences: \$60M financing for microbiome-derived therapeutics | Aug. 11, 2026

VC News Daily reported Vedanta Biosciences secured \$60M in funding. The Cambridge company develops defined bacterial consortia and other microbiome-based approaches for immune-mediated and infectious diseases.

HDIG take: Life-science relevance: microbiome therapeutics remain a technically complex but strategically important modality.

[LINK](#)

8. Flagler Health: \$50M Series B for AI-native musculoskeletal care operations | Aug. 11, 2026

VC News Daily reported Flagler Health raised a \$50M Series B, bringing total funding to \$63M. CB Insights lists Bessemer Venture Partners as lead, with SignalFire, Tribeca Venture Partners, Alumni Ventures and others participating.

HDIG take: Healthcare IT: targets the administrative and clinical-operating layer for MSK clinics, a large specialty-care cost center.

[LINK](#); [LINK](#)

9. Remepy: \$36M Series A for AI-enabled hybrid drug development | Aug. 12, 2026

VC News Daily reported Remepy closed a \$36M Series A led by O.G. Venture Partners and M Ventures. CB Insights also tracked Merck/M Ventures, NFX, Vine Ventures, Qumra Capital, PsyMed Ventures and others in the round.

HDIG take: Digital therapeutics meets pharma: combines traditional drug candidates with software-driven digital protocols. [LINK](#);

[LINK](#)

10. Teal Health: \$21.2M Series A for at-home cervical cancer screening | Aug. 12, 2026

CB Insights tracked a \$21.2M Series A for Teal Health, with .406 Ventures, Forerunner Ventures and Yosemite Ventures participating. The company offers the Teal Wand for at-home cervical cancer screening with virtual provider support.

HDIG take: Women's health: pairs device-enabled sample collection with digital clinical support in preventive cancer screening.

[LINK](#)

11. Hyku Biosciences: \$8.6M Series A for covalent small-molecule therapeutics | Aug. 13, 2026

CB Insights tracked an \$8.6M Series A for Hyku Biosciences, with Chugai Venture Fund and DROIA Ventures among investors. Hyku is building small molecules that inactivate disease-causing proteins through precise covalent targeting.

HDIG take: Drug R&D: expands the covalent-therapeutics toolkit beyond conventional cysteine-focused strategies. [LINK](#)

12. MagicRNA: Series B for engineered cell-targeted lipid nanoparticle delivery | Aug. 13, 2026

CB Insights tracked a Series B for MagicRNA, with investors including Bayland Capital, China Capital Investment Group, IDG Capital, Sino Biopharmaceutical and others. The company develops engineered cell-targeted LNPs for mRNA and nucleic-acid therapeutics.

HDIG take: Platform biotech: delivery remains one of the gating constraints for mRNA, cell therapy and immune-targeted therapeutics. [LINK](#)

Upcoming Healthcare Events

Date	Event	Location	Why it matters
Sep. 9-10 / Sep. 15, 2026	Baird 2026 Global Healthcare Conference	Virtual / New York, NY	Baird's flagship healthcare-sector investor event, including a virtual private-company track and an in-person healthcare conference day.

Date	Event	Location	Why it matters
Sep. 14-17, 2026	Becker's 11th Annual Health IT + Digital Health + RCM Annual Meeting	Chicago, IL	Large health-system operator meeting focused on AI, digital health, revenue cycle, EHR modernization and technology strategy.
Sep. 17, 2026	Southeast Healthcare Innovation Summit 2026	Atlanta, GA	Bamberg Health summit covering digital transformation, AI, diagnostics, health-system optimization, investment strategy and rural access.

Bamberg Health note: *The Portugal Healthcare Innovation Summit by Bamberg Health is scheduled for September 23, 2026, just outside this one-month event window; the September 17 Southeast Healthcare Innovation Summit is included above.*